Drugs / BAY94-9027
BAY94-9027
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01184820 | Oct 2010 → Oct 2011 | hemophilia A | Bayer | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01580293 | Apr 2012 → Jun 2014 | hemophilia A | Bayer | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01775618 | May 2013 → Mar 2015 | hemophilia A | Bayer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 94-9027 | “BAY 94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) with site-specific attachment of poly(ethylene glycol) that has shown an extended half-life in animal models...” PMID 24843882 ↗ Apr 20145“PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A.” PMID 33724632 ↗ Mar 2021 “Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A” NCT01775618 ↗ “receiving damoctocog alfa pegol (BAY 94-9027; Jivi®) prophylaxis.” PMID 37113811 ↗ Apr 2023 |
| Known as | damoctocog alfa pegol | “PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A.” PMID 33724632 ↗ Mar 20211“receiving damoctocog alfa pegol (BAY 94-9027; Jivi®) prophylaxis.” PMID 37113811 ↗ Apr 2023 |
| Known as | Jivi | “receiving damoctocog alfa pegol (BAY 94-9027; Jivi®) prophylaxis.” PMID 37113811 ↗ Apr 2023 |
| Action | Restore | “how well the study drug corrects the factor VIII levels in your blood” NCT01184820 ↗ |
| Modality | Protein / enzyme biologic | “BAY 94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII)” PMID 24843882 ↗ Apr 2014 |
| Route | Intravenous | “Single dose of Kogenate FS and 16 doses of BAY94-9027 given 2 times a week for 8 weeks. Both drugs to be given intravenously.” NCT01184820 ↗ |